Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9464524 | 0.87 | CA12 (0.61) | ALDH1A1CA12CA7CA14CA9 | |
| SCHEMBL4617795 | 0.86 | SFRP1 (0.67) | ALDH1A1CA12CA7CA14CA9 | |
| SCHEMBL4617937 | 0.86 | ATM (0.69) | ALDH1A1ATMMEP1BSFRP1AKR1C3 | |
| SCHEMBL4617234 | 0.85 | SFRP1 (0.64) | ALDH1A1CA12CA7CA14CA9 | |
| SCHEMBL4617169 | 0.85 | SFRP1 (0.57) | ALDH1A1ATMSFRP1MAPK1KMT2A | |
| SCHEMBL4617581 | 0.83 | ATM (0.55) | ALDH1A1ATMMEP1BSFRP1AKR1C3 | |
| SCHEMBL4617091 | 0.82 | MAPK1 (0.61) | ALDH1A1SFRP1MAPK1KMT2A | |
| SCHEMBL4618001 | 0.80 | MAPK1 (0.76) | ALDH1A1SFRP1MAPK1KMT2A | |
| SCHEMBL4619610 | 0.80 | MAPK1 (0.53) | ALDH1A1ATMSFRP1AKR1C3CYP2C19 | |
| SCHEMBL28147718 | 0.79 | ALDH1A1 (0.71) | ALDH1A1CA12CA7CA14CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ALDH1A1 1865/4885CA12 1740/4885CA7 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.